Journal
CLINICAL OPHTHALMOLOGY
Volume 9, Issue -, Pages 1759-1766Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OPTH.S87043
Keywords
aflibercept; age-related macular degeneration; bevacizumab; ranibizumab; vascular endothelial growth factors
Categories
Funding
- Regeneron, Inc.
Ask authors/readers for more resources
The statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline. Purpose: Switching therapies in neovascular age-related macular degeneration (AMD) may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI) in subjects previously treated with ranibizumab and/or bevacizumab. Methods: Subjects (n=26) were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST) measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA) early treatment in diabetic retinopathy study (ETDRS) letter score were obtained. Additionally, the percentage of subjects who gained or lost >= 15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated. Results: There was a mean decrease in CST of -50.3 mu m (P<0.001) and a mean increase in ETDRS BCVA of +9.2 letters (P<0.001). Twenty-seven percent of subjects experienced a > 15-letter improvement in visual acuity, and no subject lost >3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12. Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available